GPCR: Structure Therapeutics, Inc.
About
Structure Therapeutics, Inc. is a clinical stage global biopharmaceutical company, which engages in developing novel oral therapeutics to treat a wide range of chronic diseases with unmet medical needs. The company was founded by Raymond Stevens in February 2019 and is headquartered in South San Francisco, CA.
Current Value
$32.781 Year Return
Current Value
$32.781 Year Return
Key Details
Market Cap
$1.88B
P/E Ratio
-14.8
1Y Stock Return
-36.14%
1Y Revenue Growth
0.00%
Dividend Yield
0.00%
Price to Book
2.1
Strategies that include GPCR
Stock's related to GPCR
Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| HZO | 40.43% | $668.35M | -1.96% | 0.00% |
| COHR | 39.45% | $16.12B | +196.84% | 0.00% |
| PCT | 34.99% | $1.93B | +208.73% | 0.00% |
| PGEN | 33.87% | $228.91M | -28.00% | 0.00% |
| LNTH | 33.21% | $5.52B | +16.60% | 0.00% |
| AGIO | 31.34% | $3.10B | +148.79% | 0.00% |
| PRTA | 26.76% | $756.01M | -56.52% | 0.00% |
| DNLI | 25.13% | $3.50B | +33.66% | 0.00% |
| NTLA | 24.16% | $1.44B | -50.35% | 0.00% |
| ARWR | 23.45% | $2.31B | -34.44% | 0.00% |
| ACET | 22.96% | $84.87M | -10.43% | 0.00% |
| BTCT | 22.80% | $42.61M | +353.33% | 0.00% |
| OMER | 22.52% | $349.44M | +258.93% | 0.00% |
| CRSP | 22.42% | $4.01B | -30.49% | 0.00% |
| KSS | 22.16% | $1.89B | -25.17% | 11.94% |
| WOOF | 22.15% | $1.11B | +4.37% | 0.00% |
| ONEW | 21.77% | $281.57M | -26.61% | 0.00% |
| LAD | 21.74% | $9.87B | +38.08% | 0.56% |
| ARGX | 21.66% | $34.68B | +17.58% | 0.00% |
| SNDX | 21.48% | $1.35B | +2.87% | 0.00% |
Uncorrelated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| LUMN | <0.01% | $7.85B | +486.36% | 0.00% |
| CHGG | 0.01% | $175.24M | -83.42% | 0.00% |
| K | -0.01% | $27.77B | +52.50% | 2.79% |
| TAK | -0.01% | $43.18B | -2.85% | 2.17% |
| UUU | -0.01% | $4.97M | -41.89% | 0.00% |
| PCH | 0.01% | $3.28B | -11.32% | 4.36% |
| SLGN | -0.02% | $5.80B | +30.44% | 1.38% |
| EMBC | -0.02% | $777.82M | -20.98% | 4.49% |
| PBR | -0.02% | $52.88B | -8.22% | 5.68% |
| ISRG | -0.03% | $191.92B | +72.80% | 0.00% |
| EAT | 0.03% | $5.43B | +244.22% | 0.00% |
| SOUN | 0.04% | $2.34B | +207.08% | 0.00% |
| UGI | -0.04% | $5.23B | +10.82% | 6.19% |
| LOPE | -0.04% | $4.70B | +18.15% | 0.00% |
| NFE | 0.04% | $2.29B | -74.75% | 3.32% |
| CLLS | 0.05% | $141.30M | -30.99% | 0.00% |
| NINE | 0.05% | $49.99M | -42.44% | 0.00% |
| INSW | 0.05% | $2.07B | +1.70% | 1.14% |
| VTYX | -0.06% | $125.87M | -23.61% | 0.00% |
| LOB | -0.06% | $2.08B | +41.52% | 0.26% |
Inversely Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| ZIMV | -35.15% | $363.48M | +47.32% | 0.00% |
| X | -22.36% | $8.76B | +13.32% | 0.51% |
| GSK | -22.13% | $68.24B | -5.43% | 4.71% |
| WM | -19.75% | $87.92B | +27.58% | 1.34% |
| OMAB | -17.26% | $2.72B | -3.17% | 7.42% |
| PAC | -16.53% | $8.16B | +31.59% | 0.00% |
| KR | -15.90% | $42.03B | +35.08% | 2.11% |
| EOG | -15.38% | $76.03B | +10.19% | 2.70% |
| SOLV | -15.33% | $11.58B | -16.19% | 0.00% |
| VIST | -14.46% | $4.75B | +67.10% | 0.00% |
| PARR | -14.36% | $955.10M | -50.29% | 0.00% |
| SU | -13.94% | $52.05B | +23.58% | 3.92% |
| AIFU | -13.80% | $67.49M | -83.02% | 0.00% |
| MTDR | -13.52% | $7.21B | -1.21% | 1.47% |
| HAL | -13.49% | $26.77B | -20.26% | 2.20% |
| AFL | -13.22% | $61.74B | +35.69% | 1.35% |
| OVV | -13.07% | $11.61B | -0.16% | 2.69% |
| GIS | -13.07% | $34.85B | -2.91% | 3.78% |
| PGR | -13.02% | $149.10B | +57.29% | 0.45% |
| VRN | -13.01% | $3.23B | -25.43% | 6.21% |
ETF's related to GPCR
News
Finnhub
SAN FRANCISCO - Structure Therapeutics Inc. , a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and cardiopulmonary diseases, today...
Yahoo
First patients dosed in Phase 2b ACCESS study of GSBR-1290 for obesity Oral small molecule amylin receptor agonist development candidate expected to be selected by the end of 2024 Strong financial position with cash, cash equivalent and short-term investments of $915.3 million expected to fund projected operations and key clinical milestones through at least 2027 Conference Call to discuss GSBR-1290 ACCESS development program today at 4:30 p.m. ET SAN FRANCISCO, Nov. 13, 2024 (GLOBE NEWSWIRE) --
Yahoo
Phase 2b ACCESS study designed to evaluate multiple doses up to 120 mg of GSBR-1290 over 36 weeks Comprehensive development program also includes Phase 2 ACCESS II study to evaluate even higher doses of GSBR-1290 over 36 weeks; first patient expected to be dosed by end of 2024 Topline data from both ACCESS and ACCESS II studies expected in the fourth quarter of 2025 Company to host conference call today at 4:30 p.m. Eastern Time SAN FRANCISCO, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Structure Therapeu
Finnhub
Structure Therapeutics Reports Third Quarter 2024 Financial Results and Recent Highlights First patients dosed in Phase 2b ACCESS study of GSBR-1290 for obesity Oral...
Finnhub
SAN FRANCISCO - Structure Therapeutics Inc. , a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and pulmonary diseases, today announced...
Yahoo
SAN FRANCISCO, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and pulmonary diseases, today announced multiple upcoming posters at The Obesity Society's Annual Meeting, ObesityWeek®, taking place from November 3-6, 2024 in San Antonio, TX. Title: Novel Oral Small Molecule Dual Amylin and Calcitonin Receptor Agonists for Obesity TreatmentPoster Number: P
Disclaimer
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.